Navigation Links
Scott & White Healthcare clinical trials target lymphoma, leukemia
Date:5/5/2010

Scott & White's Cancer Research Institute (CRI) is participating in an international study that targets adult relapsed or refractory B-cell Non-Hodgkin's lymphoma and chronic lymphocytic leukemia.

"This study is important in our efforts to find new and better ways to treat patients with leukemia or lymphoma," said Arthur E. Frankel, M.D., director of Scott & White's Cancer Research Institute, and principal investigator for the Temple portion of the study. "Scott & White, as well as the entire Central Texas community, are fortunate to be included in this international research."

The Phase I/II study is open to eligible patients with previously treated B-cell non-Hodgkin's lymphoma (NHL), B-cell chronic lymphocytic leukemia (CLL), to include small lymphocytic lymphoma (SLL). B-cell lymphomas account for 80-90% of all Non-Hodgkin's Lymphomas. The clinical trial will evaluate the safety, tolerability, and efficacy of an investigative therapeutic research agent called CAT-8015.

This research will ultimately include 30 sites in the U.S., Canada and Europe and from 110 to 140 subjects. The study will last about 30 months.

"We want to determine if this agent is effective in destroying cancer cells using varying doses," said Dr. Frankel.

Descriptions:

  • Chronic lymphocytic leukemia (CLL), more common in people age 60 and older, is a B-cell disorder in which white blood cells live longer than normal and accumulate in the blood and bone marrow and sometimes the lymph nodes. This accumulation of white blood cells crowds out healthy lymphocytes and causes immune system problems. About 15,490 new cases of CLL were diagnosed in 2009.
  • CLL and Small Lymphocytic Lymphoma (SLL) are the same disease with slight variations. When the cancer cells are primarily in the lymph nodes, it's called SLL.
  • Follicular Lymphoma, a slow-growing Lymphoma, accounts for 20-30% of the cases of Non-Hodgkin's Lymphoma. It occurs equally among males and female adults over the age of 60.
  • Diffuse Large B-Cell Lymphoma is an aggressive Non-Hodgkin's Lymphoma (NHL) that occurs in B-cells, and accounts for two out of five cases of NHL.
  • Mantle cell lymphoma (MCL) accounts for about 1 in 20 Non-Hodgkin's Lymphoma diagnoses in the United States; and typically occurs in patients over 30 years old, most frequently in males over the age of 50.


'/>"/>

Contact: Katherine Voss
kvoss@swmail.sw.org
254-724-4097
Scott & White Healthcare
Source:Eurekalert

Related medicine news :

1. Scottsdale Veterinary Pharmacy Celebrates Success in Business By Dodging Veterinary Drug Shortages
2. New Varicose Vein Treatment Center Opens in Prescott, Arizona
3. Scott & White Healthcare researchers studying investigational agent that targets breast cancer
4. Allergy Relief, Chiropractic and Biofeedback Provided at New Absolute Health Clinic in Scottsdale, Arizona
5. SUNZ Insurance Company Selects Scott Robertson as President
6. James Scott Farrin Supports Radiothon for Duke Children's Hospital
7. Scott & White Healthcare pathologist is co-investigator on breast cancer study
8. Scott & White Memorial Hospital uses device to revolutionize treatment of traumatic aortic injury
9. Trustmark and HealthFitness Announce Early Termination of Hart-Scott-Rodino Waiting Period
10. Scott Roeder Trial: Randall Terry, Operation Rescue Founder and Insurrecta Nex Members to Attend Trial in Wichita
11. New study shows TGen spin-off boosts Scottsdale economy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... ... athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as ... City area —Johnson is one of the first doctors to perform the treatment. ...
(Date:6/24/2016)... ... , ... A recent article published June 14 on E Online ... on to state that individuals are now more comfortable seeking to undergo not only ... calf and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians (BHP) ...
(Date:6/24/2016)... ... ... Marcy was in a crisis. Her son James, eight, was out of control. Prone to ... , “When something upset him, he couldn’t control his emotions,” remembers Marcy. “If there ... my other children and say he was going to kill them. If we were ...
(Date:6/24/2016)... CA (PRWEB) , ... June 24, 2016 , ... ... is now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience ... Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is ...
(Date:6/24/2016)... TX (PRWEB) , ... June 24, 2016 , ... People ... part in Genome magazine’s Code Talker Award, an essay contest in which patients and ... an award to be presented at the 2016 National Society of Genetic Counselors (NSGC) ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... -- Dehaier Medical Systems Ltd. (NASDAQ: DHRM ... sells medical devices and wearable sleep respiratory products in ... agreement with Hongyuan Supply Chain Management Co., Ltd. (hereinafter ... 2016, to develop Dehaier,s new Internet medical technology business. ... leverage Hongyuan Supply Chain,s sales platform to reach Dehaier,s ...
(Date:6/24/2016)... , June 24, 2016 ... Market by Type (Standard Pen Needles, Safety Pen Needles), ... (Insulin, GLP-1, Growth Hormone), Mode of Purchase (Retail, Non-Retail) ... MarketsandMarkets, This report studies the market for the forecast ... to reach USD 2.81 Billion by 2021 from USD ...
(Date:6/24/2016)... 24, 2016  Arkis BioSciences, a leading innovator ... more durable cerebrospinal fluid treatments, today announced it ... funding is led by Innova Memphis, followed by ... private investors.  Arkis, new financing will accelerate the ... market release of its in-licensed Endexo® technology. ...
Breaking Medicine Technology: